CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 522 enrolled
Drug / intervention
Accu-Chek 360° View Blood Glucose Analysis Tool +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00674986
NCT00674986N/ACompleted

A Clinical Study to Evaluate the Use of Episodic, Intensive Blood Glucose Monitoring in Persons With Non-insulin Treated Type 2 Diabetes

Hoffmann-La Roche·interventional·Posted May 8, 2008·Updated Oct 21, 2013

In Brief

A clinical study evaluating Accu-Chek 360° View Blood Glucose Analysis Tool and Accu-Chek Aviva Glucose Meter for Diabetes Mellitus, Type 2. Completed, enrolled 522 participants across 29 sites.

Detailed Summary

This randomized, parallel group study will determine whether the use of episodic, intensive glucose monitoring via the Accu-Chek 360 view blood glucose analysis system has a positive effect on overall glycemic control. Patients will be randomized into either the 'usual care' group, or the 'interventional group' supplemented with the Accu-Chek 360 view blood glucose analysis system. The effect of each treatment regimen on glycemic control will be assessed by measurement of change in baseline HbA1c values at 12 months. The anticipated time on study treatment is 1 year, and the target sample size is 504 individuals.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 8, 2008
Enrollment StartMar 1, 2008
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 18.2 years ago

Interventions

Accu-Chek 360° View Blood Glucose Analysis Tooldevice

Accu-Chek Aviva Glucose Meterdevice